A range of targeted treatments using monoclonal antibodies in dermatology. Actuality and futurology;Panoplies des thérappies ciblées par anticorps monoclonaux en dermatologie: Actualité et prospectives

Revue Medicale de Liege

Volumn 64, Issue 5-6, 2009, Pages 334-338

  Pierard Franchimont C ^a   Quatresooz, P ^a   Paquet, P ^a   Nikkels, A F ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atopic dermatitis; Carcinoma; Lymphoma; Melanoma; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; CETUXIMAB; ETANERCEPT; INFLIXIMAB; IPILIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; OMALIZUMAB; RITUXIMAB; TICILIMUMAB; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; DERMATOLOGICAL AGENT;

APHTHOUS STOMATITIS; ATOPIC DERMATITIS; BIOLOGICAL THERAPY; CARCINOMA; DERMATOLOGY; DRUG ANTAGONISM; GRAFT VERSUS HOST REACTION; HIDRADENITIS; HUMAN; MELANOMA; PATIENT SELECTION; PEMPHIGUS; PSORIASIS; REVIEW; SKIN DISEASE; SKIN LYMPHOMA; SKIN TUMOR; TREATMENT RESPONSE; ARTICLE;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; SKIN DISEASES;

EID: 67749110096     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Mittmann N, Chan B, Knowles S, et al.- Intravenous immunoglobulin use in patients with toxic epidermalnecrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol, 2006, 7, 359-368.
2. Paquet P, Kavery S, Jacob E, et al.- Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol, 2006, 15, 381-386.
3. Suen JK, Bressler L, Shord SS, et al.- Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs, 2007, 18, 827-829.
4. Specenier P, Vermorken J.- The role of cetuximab in the treatment of head and neck cancer. Belg J Med Oncol, 2008, 2, 161-167.
5. Lacouture ME, Desai A, Soltani K, et al.- Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol, 2006, 31, 783-785.
6. Hermanns JF, Piérard GE, Quatresooz P.- Erlotinib-responsive actinic keratoses. Oncol Reports, 2007, 18, 581-584.
7. Quatresooz P, Piérard-Franchimont C, Paquet P, et al.- Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol, 2008, 18, 6-10.
8. Lane JE, Cheyney JM, Lane TN, et al.- Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol, 2006, 54, 68-72.
9. Vigo PG, Girgis KR, Pfuetze BL, et al.- Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol, 2006, 55, 168-169.
10. Belloni B, Ziai M, Lima A, et al.- Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol, 2007, 120, 1223-1225.
11. Krathen RA, Hsu S.- Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol, 2005, 53, 338-340.
12. Moul DK, Korman NJ.- Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol, 2006, 142, 1110-1112.
13. Fernandez-Vozmediano JM, Armario-Hita JC.- Infliximab for the treatment of hidradenitis suppurativa. Dermatology, 2007, 215, 41-44.
14. Mekkes JR, Bos JD.- Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Brit J Dermatol, 2008, 158, 370-374.
15. Burg G, Kempf W, Cozzio A, et al.- WHO/EORTC classification of cutaneous lymphomas 2005 : histological and molecular aspects. J Cutan Pathol, 2005, 32, 647-674.
16. Quatresooz P, Piérard-Franchimont C, Piérard GE.- Comment j'explore... un lymphome T cutané. Nouveaux horizons. Rev Med Liège, 2008, 63, 208-212.
17. Ure UB, Ar MC, Salihoglu A, et al.- Alemtuzumab in Sézary syndrome : efficient but not innocent. Eur J Dermatol, 2007, 18, 525-529.
18. Grey M.- Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin. Br J Haematol, 2008, 142, Epub 208, May 8.
19. Piérard GE, Soyeur-Broux M, Fridman V, et al.- Lymphome angiotrope de type angioendothéliomatose proliférative systémique. Ann Dermatol Venereol, 1988, 115, 427-431.
20. Prajapati V, Mydlarski PR.- Rituximab : a B-cell depletion therapy for dermatologic disease. Skin Therapy Lett, 2007, 12, 6-9.
21. Shimaka K, Kosugi H, Narimatsu H, et al.- Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma. J Clin Exp Hematol, 2008, 48, 25-28.
22. Claessens N, Piérard GE, Piérard-Franchimont C, et al.- Immunohisto-chemical detection of incipient melanoma micrometastases; Relationship with sentinel lymph node involvement. Melanoma Res, 2005, 15, 107-110. (Pubitemid 40637988)
23. Quatresooz P, Arrese JE, Piérard-Franchimont C, Piérard GE.- Immunohistochemical aid at risk stratification of melanocytic neoplasms. Int J Oncol, 2004, 24, 211-216.
24. Quatresooz P, Arrese JE, Piérard-Franchimont C, Piérard GE.- Molecular histology on the diagnostic cutting edge between malignant melanomas and melanocytomas. Exp Rev Dermatol, sous presse.
25. Crammer LD, Hersh E.- The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest, 2007, 25, 613-631. (Pubitemid 350135746)
26. O'Day SJ, Hamid O, Urba WI.- Targeting cytotoxic T-lymphocyte antigen-4 (CTLA4) : a novel strategy for the treatment of melanoma and other malignancies. Cancer, 2007, 15, 2614-2627. (Pubitemid 350250330)
27. Camacho LH.- Novel therapies targeting the immune system : CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. Expert Opin Invest Drugs, 2008, 17, 371-385. (Pubitemid 351578189)
28. Comin-Anduix B, Lee Y, Jalil J, et al.- Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associate-antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med, 2008, 6, 22. (Pubitemid 351803824)
29. Saenger YM, Wolchok JD.- The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma : patient cases. Cancer Immun, 2008, 17, 1.
30. Paquet P, Piérard GE.- New insights in toxic epidermal necrolysis (Lyell's syndrome)- clinical consideration, pathobiology and targeted treatments revisited. Am J Clin Dermatol, sous presse.
31. Fischer M, Fiedler E, Marsch WC, Wohlrab J.- Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol, 2002, 146, 707-708. (Pubitemid 34437794)
32. Hunger R, Hunziker T, Buettiker U, et al.- Rapid resolution of toxic epidermal necrolysis with anti-TNFα treatment. J Allergy Clin Immunol, 2005, 116, 923-924. (Pubitemid 41400562)
33. Al-Shouli S, Abouchala N, Bogusz M, et al.- Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol, 2005, 85, 534-535. (Pubitemid 43087298)
34. Meiss F, helmbold P, Meykadeh V, et al.- Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis : response to antitumor necrosis factor-α antibody infliximab : report of three cases. J Eur Acad Dermatol Venereol, 2007, 21, 717-719. (Pubitemid 46916796)
35. Niedermeier A, Wörl P, Barth S, et al.- Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol, 2006, 16, 266-270. (Pubitemid 43736147)
36. Cianchini G, Corona R, Frezzolini A, et al.- Treatment of severe pemphigus with rituximab. Arch Dermatol, 2007, 143, 1033-1038.
37. Sobell JM, Kalb RE, Weinberg JM.- Management of moderate to severe plaque psoriasis (part 1) : clinical update on antitumor necrosis factor agents. J Drugs Dermatol, 2009, 8, 147-154.
38. Sobell JM, Kalb RE, Weinberg JM.- Management of moderate to severe plaque psoriasis (part 2) : clnical update on T-cell modulators and investigational agents. J Drugs Dermatol, 2009, 8, 230-238.
39. Nijsten T, Spuls PL.- Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. Br J Dermatol, 2008, 159, 257-258. (Pubitemid 351874491)
40. Saurat JH, Stingl G, Dubertret L, et al.- Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol, 2008, 158, 558-566. (Pubitemid 351239154)
41. Bedini C, Nasorri F, Girolomoni G, et al.- Anti-TNF-alpha chimeric antibody (Infliximab) inhibits activation of psoriatic CD4+ and CD8+ T lymphocytes and impairs dendritic cell functions. Br J Dermatol, 2007 157, 249-258. (Pubitemid 47083831)
42. Reich K, Nestle FO, Wu, Y, et al.- Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol, 2007, 17, 381-386. (Pubitemid 47425903)
43. Serrao VV, Martins A, Lopes MJ.- Infliximab in recalcitrant generalized pustular arthropatic psoriasis. Eur J Dermatol, 2008, 18, 71-73. (Pubitemid 351158176)
44. Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V.- Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology, 2008, 216, 312-316. (Pubitemid 351630095)
45. Reich K, Sinclair R, Roberts G, et al.- Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis : a meta-analysis. Curr Med Res Opin, 2008, 24, 1237-1254. (Pubitemid 351741556)
46. Schmitt-Egenolf M.- Switching biologicals : switching TNFα antagonists in psoriasis treatment. Dermatology, 2008, 216, 281-282. (Pubitemid 351630091)
47. Sterry W, Barker J, Boencke H, et al.- Biological therapies in the systemic management of psoriasis. International Consensus Conference. Br J Dermatol, 2004, 151, 3-17. (Pubitemid 39215184)
48. Leonardi CL, Kimball AB, Papp KA, et al.- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis : 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371, 1665-1674. (Pubitemid 351671883)
49. Papp K, Langley RG, Lebwohl M, et al.- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis : 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 2008, 371, 1675-1684. (Pubitemid 351671884)
50. Kohno T, Tam LTT, Stevens SR, Louie JS.- Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Invest Dermatol Symp Proc, 2007, 12, 5-8. (Pubitemid 46763031)
51. Tan JK, Aphale A, Malavita R, et al.- Mechanisms of action of etanercept in psoriasis. J Invest Dermatol Symp Proc, 2007, 12, 38-45.
52. Haider AS, Cardinale IR, Whynot JA, Krueger JG.- Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Invest Dermatol Symp Proc, 2007, 12, 9-15. (Pubitemid 46763029)
53. Altomare G, Ayala F, Berardesca E, et al.- Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol Ther, 2008, 21, S1-S14.
54. Brimhall AK, King LN, Licciardone JC, et al.- Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis : a meta-analysis of randomized controlled trials. Br J Dermatol, 2008, 159, 274-285. (Pubitemid 352009861)
55. Krueger GG, Gottlieb AB, Sterry W, et al.- A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatol Treat, 2008, 19, 146-155. (Pubitemid 351882998)
56. Sugiyama H, McCormick TS, Cooper KD, Korman NJ.- Alefacept in the treatment of psoriasis. Clin Dermatol, 2008, 26, 503-508.
57. Bansal C, Leonardi CL, Van Voorhees AS.- Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy. Int J Dermatol, 2008, 47, 1204-1206.
58. Cutler C, Miklos D, Kim HT, et al.- Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, 108, 756-762. (Pubitemid 44061381)
59. Sanchez-Cano D, Callejas-Rubio J, Ruiz-Villaverde R, Ortego-Centeno N.- Recalcitrant, recurrent aphthous stomatitis successfully treated with adalimumab. J Eur Acad Dermatol Venereol, 2009, 23, 206.